Rocket Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Business Wire
– Initiated Phase 1 Trial for FA “Process B” Using a Modified Cell Enrichment Process, Transduction Enhancers, and Commercial-Grade Vector Manufacturing and Cell Processing – – Successful Closing of $90.6 Million Equity Offering to Support Pipeline – – On Track for Clinical Data on Two of Four Gene Therapy Programs by Year End – NEW YORK--(BUSINESS WIRE)-- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, reports financial results for the quarter ended March 31, 2019, and provides an update on the Company's recent achievements, as well as upcoming milestones. “Last quarter, we continued to lay the groundwork towards achieving our objective of having four programs in the clinic by year end,” said Gaurav Shah, M.D., Chief Executive Officer and President of Rocket. “We initiated our Phase 1
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $53.00 price target on the stock.MarketBeat
- Rocket Pharmaceuticals: Cautiously Optimistic (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals: Multiple Regulatory Submissions Make It A Must Watch [Seeking Alpha]Seeking Alpha
- Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "neutral" rating and a $39.00 price target on the stock.MarketBeat
RCKT
Earnings
- 2/26/24 - Beat
RCKT
Sec Filings
- 4/22/24 - Form 144
- 4/17/24 - Form PRE
- 4/16/24 - Form 4
- RCKT's page on the SEC website